82 related articles for article (PubMed ID: 21997313)
21. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.
Akisik E; Dalay N
Exp Mol Pathol; 2004 Jun; 76(3):260-3. PubMed ID: 15126109
[TBL] [Abstract][Full Text] [Related]
22. Significance of alterations in plasma lipid profile levels in breast cancer.
Franky Dhaval Shah ; Shilin Nandubhai Shukla ; Pankaj Manubhai Shah ; Patel HR; Prabhudas Shankerbhai Patel
Integr Cancer Ther; 2008 Mar; 7(1):33-41. PubMed ID: 18292593
[TBL] [Abstract][Full Text] [Related]
23. The relationship between apolipoprotein (apo) E polymorphism and lipid changes: An 8-year cohort study in Beijing elderly persons.
Guan S; Yang J; Tang Z; Fang X; Wu X; Sun F; Liu H; Chan P
Arch Gerontol Geriatr; 2012; 55(3):713-7. PubMed ID: 22206590
[TBL] [Abstract][Full Text] [Related]
24. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim.
Rutter JL; Chatterjee N; Wacholder S; Struewing J
Epidemiology; 2003 Nov; 14(6):694-700. PubMed ID: 14569185
[TBL] [Abstract][Full Text] [Related]
25. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer.
Love RR; Newcomb PA; Wiebe DA; Surawicz TS; Jordan VC; Carbone PP; DeMets DL
J Natl Cancer Inst; 1990 Aug; 82(16):1327-32. PubMed ID: 2199681
[TBL] [Abstract][Full Text] [Related]
26. The Srb1+1050T allele is associated with metabolic syndrome in children but not with cholesteryl ester plasma concentrations of high-density lipoprotein subclasses.
Juárez-Meavepeña M; Carreón-Torres E; López-Osorio C; García-Sánchez C; Gamboa R; Torres-Tamayo M; Fragoso JM; Rodríguez-Pérez JM; Vargas-Alarcón G; Pérez-Méndez O
Metab Syndr Relat Disord; 2012 Apr; 10(2):110-6. PubMed ID: 22182283
[TBL] [Abstract][Full Text] [Related]
27. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
28. Association of adiponectin (ADIPOQ) rs2241766 polymorphism and dyslipidemia in HIV/HCV-coinfected patients.
Pineda-Tenor D; Berenguer J; García-Broncano P; Jiménez-Sousa MA; Fernández-Rodríguez A; Diez C; García-Álvarez M; Carrero A; Catalán P; Aldámiz-Echevarria T; Resino S
Eur J Clin Invest; 2014 May; 44(5):453-62. PubMed ID: 24528335
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen, serum lipoproteins and cardiovascular risk.
Bruning PF; Bonfrer JM; Hart AA; de Jong-Bakker M; Linders D; van Loon J; Nooyen WJ
Br J Cancer; 1988 Oct; 58(4):497-9. PubMed ID: 3207604
[TBL] [Abstract][Full Text] [Related]
30. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study.
Wasan KM; Goss PE; Pritchard PH; Shepherd L; Tu D; Ingle JN
Breast Cancer Res Treat; 2012 Dec; 136(3):769-76. PubMed ID: 23089983
[TBL] [Abstract][Full Text] [Related]
31. Her2 genotype and breast cancer progression in Korean women.
An HJ; Kim NK; Oh D; Kim SH; Park MJ; Jung MY; Kang H; Kim SG; Lee KP; Lee KS
Pathol Int; 2005 Feb; 55(2):48-52. PubMed ID: 15693849
[TBL] [Abstract][Full Text] [Related]
32. Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.
Cresti N; Lee J; Rourke E; Televantou D; Jamieson D; Verrill M; Boddy AV
Eur J Cancer; 2016 Mar; 55():27-37. PubMed ID: 26773371
[TBL] [Abstract][Full Text] [Related]
33. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen.
Ntukidem NI; Nguyen AT; Stearns V; Rehman M; Schott A; Skaar T; Jin Y; Blanche P; Li L; Lemler S; Hayden J; Krauss RM; Desta Z; Flockhart DA; Hayes DF;
Clin Pharmacol Ther; 2008 May; 83(5):702-10. PubMed ID: 17713466
[TBL] [Abstract][Full Text] [Related]
35. Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy.
Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Schwartz DC
Clin Chim Acta; 1993 Dec; 223(1-2):43-52. PubMed ID: 8143369
[TBL] [Abstract][Full Text] [Related]
36. Association between ABCG1 polymorphism rs1893590 and high-density lipoprotein (HDL) in an asymptomatic Brazilian population.
Zago VH; Scherrer DZ; Parra ES; Panzoldo NB; Alexandre F; Nakandakare ER; Quintão EC; de Faria EC
Mol Biol Rep; 2015 Mar; 42(3):745-54. PubMed ID: 25398214
[TBL] [Abstract][Full Text] [Related]
37. Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer.
Thangaraju M; Kumar K; Gandhirajan R; Sachdanandam P
Cancer; 1994 Feb; 73(3):659-63. PubMed ID: 8299087
[TBL] [Abstract][Full Text] [Related]
38. Association of HER2 codon 655 polymorphism with ovarian cancer.
Watrowski R; Castillo-Tong DC; Schuster E; Fischer MB; Speiser P; Zeillinger R
Tumour Biol; 2016 Jun; 37(6):7239-44. PubMed ID: 26666819
[TBL] [Abstract][Full Text] [Related]
39. Polymorphism rs4919510:C>G in mature sequence of human microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes.
Huang AJ; Yu KD; Li J; Fan L; Shao ZM
PLoS One; 2012; 7(5):e35252. PubMed ID: 22586447
[TBL] [Abstract][Full Text] [Related]
40. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen.
Rössner S; Wallgren A
Atherosclerosis; 1984 Sep; 52(3):339-46. PubMed ID: 6497936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
